Biography

Sherri-Ann M. Burnett-Bowie MD, MPH is an Assistant Professor of Medicine at Harvard Medical School and a clinical investigator in the Massachusetts General Hospital (MGH) Endocrine Unit, where her research focuses on defining the physiology of a new mineral metabolism hormone, FGF23; skeletal and non-skeletal effects of vitamin D; and clinical trials of treatments for osteoporosis.  She cares for patients seen at the MGH Endocrine Associates and the MGH Bone Density Center.  Dr. Burnett-Bowie is an Associate Director of the MGH Multicultural Affairs Office and the Director for Multicultural Affairs for the Department of Medicine at MGH.  Teaching and increasing diversity and inclusivity are central to her mission.

Research Intrest

Research is focused on defining the physiology of a new phosphate-regulating hormone FGF23 Skeletal and non-skeletal consequences of vitamin D deficiency Clinical trials of treatments for osteoporosis.

List of Publications
Finkelstein , JS, H. Lee, SM Burnett-Bowie et al. Gonadal steroids & body composition, strength, and sexual function in men. NEJM 2013
Tsai, JN, Uihlein, AV, H Lee et al. Teriparatide & denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013
Mitchell, DM, MP Henao, JS Finkelstein, SM Burnett-Bowie. Prevalence & predictors of vitamin D deficiency in healthy adults. JCEM 2012.
Burnett-Bowie, SM , BZ Leder, MP Henao et al. Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. CJASN 2012.
Burnett, SM, S Gunawardene, FR Bringhurst et al. Regulation of c-terminal and intact FGF23 by dietary phosphate in men and women. JBMR 2006.